Scholar Rock is trading 4.43% up now at $60.83 amid broad strength across biotechnology stocks, with XBI up 2.06% during regular trading.
- No new company-specific announcement or analyst action clearly explaining the August 26, 2026 move was identified.
- FDA review of apitegromab continues through an alternate facility; the European filing is being withdrawn for resubmission.
- The FDA decision remains targeted for September 30, 2026.